Abstracts tagged "Disease Activity"

Abstract Number: 2578 • 2014 ACR/ARHP Annual Meeting
Disease Activity Is the Major Determinant of Quality of Life and Physical Function in Patients with Early Axial Spondyloarthritis. Results from the Esperanza Cohort.
Cristina Fernández-Carballido¹, Victoria Navarro-Compán², Mireia Moreno³, Xavier Juanola⁴, Juan Mulero⁵ and Eugenio De Miguel⁶, ¹Rheumatology, University General Hospital Elda, Elda (Alicante), Spain, ²Rheumatology, University Hospital La Paz and Leiden University Medical Center, Madrid, Spain, ³Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain, ⁵Rheumatology, University Hospital Puerta de Hierro, Majadahonda (Madrid), Spain, ⁶Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain
Background/Purpose : Main objective: to describe health related quality of life (HRQoL), physical function (PF) and spinal mobility (SM) in patients with early axial Spondyloarthritis…
Abstract Number: 2387 • 2014 ACR/ARHP Annual Meeting
Relation Between Disease Activity Indices and Their Individual Components and Radiographic Progression in Rheumatoid Arthritis: A Systematic Literature Review
Victoria Navarro-Compán¹, Ana Maria Gherghe², Josef Smolen³, Daniel Aletaha⁴, Robert B. M. Landewé^5,6 and Désirée van der Heijde⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶Atrium Medical Center, Heerlen, Netherlands, ⁷Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Background/Purpose: Composite indices and single items are available to monitor disease activity in rheumatoid arthritis (RA). Their relation to radiographic progression is an important aspect…
Abstract Number: 1824 • 2014 ACR/ARHP Annual Meeting
A Randomized Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Improvement in Disease Activity and Fatigue Scores
Glauce Lima, Juliane Paupitz, Liliam Takayama, Eloisa Bonfa and Rosa M R Pereira, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose Vitamin D has an important immunomodulatory effect but there are no clinical trials that directly addressed the benefit from boosting the serum level of…
Abstract Number: 1353 • 2014 ACR/ARHP Annual Meeting
Integrating Collection of Rheumatoid Arthritis Disease Activity and Physical Function Scores into an Academic Rheumatology Practice to Improve Quality of Care
Vladimir Chernitskiy¹, Andre DeVito², Naama Neeman², Niraj Sehgal², Jinoos Yazdany³ and Andrew J. Gross³, ¹Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: The default design of our institutions’ electronic health record (EHR)(Epic Systems) was not optimally structured to systematically collect quality metrics for rheumatic disease management…
Abstract Number: 886 • 2014 ACR/ARHP Annual Meeting
Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status?
Nancy A. Baker¹, Heather Eng², Juan (June) Feng², Jason Lyons², Yong Gil Hwang³, Kimberly P. Liang⁴ and Larry W. Moreland⁵, ¹Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Disease remission is the goal of treat-to-target initiatives in rheumatoid arthritis (RA). There are multiple indices to measure disease activity and remission status including…
Abstract Number: 575 • 2014 ACR/ARHP Annual Meeting
Disease Activity Strongly Influences Work Productivity and Physical Health Related Quality of Life in Early Axial Spondyloarthritis: Data from the SPACE-Cohort
A Roeterink¹, M de Hooge², R. van den Berg², H Dagfinrud³, R Landewé⁴, M. van Oosterhout⁵, R Ramonda⁶, D. van der Heijde¹ and F van Gaalen², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo City Dept of Rheumat, Diakonhjemmet Hospital, Oslo, Norway, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Groene Hartziekenhuis, Gouda, Netherlands, ⁶Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: In early onset axial spondyloarthritis (axSpA), not much is known about the relationship between disease activity and work productivity loss (WPL) or disease activity…
Abstract Number: 365 • 2014 ACR/ARHP Annual Meeting
Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Denis Choquette¹, Dalton Sholter², Isabelle Fortin³, Michael Starr⁴, Carter Thorne⁵, Milton Baker⁶, Regan Arendse⁷, Philip Baer⁸, Michel Zummer⁹, Jude Rodrigues¹⁰, Maqbool Sheriff¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Allen J Lehman¹⁴, Susan Otawa¹⁴ and May Shawi¹³, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Scarborough, ON, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Clinical Research and Arthritis Centre, Windsor, ON, Canada, ¹¹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose DAS28 is an important outcome for clinical research and practice assisting with therapeutic decisions. The main contributors to DAS28 are joint tenderness and acute-phase…
Abstract Number: 2926 • 2014 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy
Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Sonia Cabrera-Villalba¹, Julio Ramirez¹, Andrea Cuervo¹, Virginia Ruiz-Esquide¹, Azucena González Navarro², Jordi Yagüe³, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Calprotectin is a major S100 leucocyte protein, is associated to disease activity in rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients. Calprotectin is a potentially…
Abstract Number: 2585 • 2014 ACR/ARHP Annual Meeting
Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis
Grigorios Sakellariou¹, Spyros Gerou², Dimitrios Oikonomou³ and Fares Sayegh⁴, ¹Rheumatology, 424 General Military Hospital, Thessaloniki, Greece, ²Laboratories "Analysis", Thessaloniki, Greece, ³Biopathology, 424 General Military Hospital, Thessaloniki, Greece, ⁴3rd Orthopaedic, "Papageorgiou" General Hospital, Thessaloniki, Greece
Background/Purpose: In patients with ankylosing spondylitis (AS), smoking is associated with increased disease activity and more radiographic damage. However, the mechanisms underlying the effects of…
Abstract Number: 2391 • 2014 ACR/ARHP Annual Meeting
Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice
G. Avila¹, Arnald Alonso¹, María América López-Lasanta¹, Andrea Pluma-Sanjurjo², C. Diaz² and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose Biological therapies (BTs) have greatly improved the outcomes in RA patients and nowadays clinical remission (REM) and low disease activity (LDA) have become realistic…
Abstract Number: 1809 • 2014 ACR/ARHP Annual Meeting
Is Team Care Better? a Comparison of Rheumatoid Arthritis Disease Activity Among Patients Cared for in Practices with Nurse Practitioners and Physicians Assistants Versus Rheumatologist Only
DH Solomon^1,2, Liana Fraenkel³, Bing Lu¹, Erika Brown¹, Peter Hsun Tsao⁴, Elena Losina⁵, Jeffrey N. Katz⁶ and Asaf Bitton⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁷Medicine, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The Affordable Care Act proposes more widespread use of mid-level providers (MLPs), such as nurse practitioners and physician assistants, but little is known about…
Abstract Number: 1352 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Disease Activity Assessment and Population Management Processes Used By Clinician Rheumatologists
Anne Winkler¹, James Mossell², Edmund MacLaughlin³, Drew Johnson⁴ and J. Timothy Harrington⁵, ¹Rheumatology, Winkler Medical Practice LLC, Springfield, MO, ²Arthritis & Osteo Center of South GA, Tifton, GA, ³Edmund L. MacLaughlin LLC, Cambridge, MD, ⁴Crescendo Bioscience, Inc., South San Francisco, CA, ⁵Joiner Associates LLC, Madison, WI
Background/Purpose: Timely disease activity assessment (DAA) and population management (PM) are known to reduce the burdens of chronic diseases, including RA. Currently, the measures and…
Abstract Number: 867 • 2014 ACR/ARHP Annual Meeting
Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy
Sara K. Tedeschi¹, Hongshu Guan¹, Alexander Fine¹, Bonnie L. Bermas² and Karen H. Costenbader², ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Active SLE, in particular lupus nephritis, during the six months prior to conception is associated with disease flare during pregnancy. Previous studies, however, have…
Abstract Number: 570 • 2014 ACR/ARHP Annual Meeting
Sleep Disturbances in Korean Patients with Ankylosing Spondylitis Are Associated with Increased Disease Activity
Hye-Jin Jeong¹, Yun Sung Kim², Chang-Nam Son³, Ji-Min Kim³ and Sang-Hyon Kim³, ¹Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Internal Medicine, Chosun University Hospital, Gwangju, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Sleep problems have been reported to be more frequent in rheumatic disease than normal population. Other studies indicate various sleep problems have been reported…
Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir*³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].